Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factor

Tigist Y. Tamir, Brittany M. Bowman, Megan J. Agajanian, Dennis Goldfarb, Travis P. Schrank, Trent Stohrer, Andrew E. Hale, Priscila F. Siesser, Seth J. Weir, Ryan M. Murphy, Kyle M. LaPak, Bernard E. Weissman, Nathaniel J. Moorman, M. Ben Major

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2) is a transcription factor and master regulator of cellular antioxidant response. Aberrantly high NRF2-dependent transcription is recurrent in human cancer, but conversely NRF2 activity diminishes with age and in neurodegenerative and metabolic disorders. Although NRF2-activating drugs are clinically beneficial, NRF2 inhibitors do not yet exist. Here, we describe use of a gain-of-function genetic screen of the kinome to identify new druggable regulators of NRF2 signaling. We found that the under-studied protein kinase brain-specific kinase 2 (BRSK2) and the related BRSK1 kinases suppress NRF2-dependent transcription and NRF2 protein levels in an activity-dependent manner. Integrated phosphoproteomics and RNAseq studies revealed that BRSK2 drives 5'-AMP-activated protein kinase α2 (AMPK) signaling and suppresses the mTOR pathway. As a result, BRSK2 kinase activation suppresses ribosome-RNA complexes, global protein synthesis and NRF2 protein levels. Collectively, our data illuminate the BRSK2 and BRSK1 kinases, in part by functionally connecting them to NRF2 signaling and mTOR. This signaling axis might prove useful for therapeutically targeting NRF2 in human disease.This article has an associated First Person interview with the first author of the paper.

Original languageEnglish
JournalJournal of cell science
Issue number14
StatePublished - Jul 15 2020


  • AMPK
  • BRSK1
  • BRSK2
  • Functional genomics
  • Kinase
  • NRF2
  • Oxidative stress response
  • Phosphoproteomics
  • mTOR


Dive into the research topics of 'Gain-of-function genetic screen of the kinome reveals BRSK2 as an inhibitor of the NRF2 transcription factor'. Together they form a unique fingerprint.

Cite this